ATE400301T1 - Arteriovenöse und venöse transplantatbehandlungen: methoden und zusammensetzungen - Google Patents

Arteriovenöse und venöse transplantatbehandlungen: methoden und zusammensetzungen

Info

Publication number
ATE400301T1
ATE400301T1 AT96912854T AT96912854T ATE400301T1 AT E400301 T1 ATE400301 T1 AT E400301T1 AT 96912854 T AT96912854 T AT 96912854T AT 96912854 T AT96912854 T AT 96912854T AT E400301 T1 ATE400301 T1 AT E400301T1
Authority
AT
Austria
Prior art keywords
arteriovenous
compositions
methods
compounds
extracellular matrix
Prior art date
Application number
AT96912854T
Other languages
English (en)
Inventor
Andrew Zalewski
Yi Shi
Original Assignee
Univ Jefferson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Jefferson filed Critical Univ Jefferson
Application granted granted Critical
Publication of ATE400301T1 publication Critical patent/ATE400301T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT96912854T 1995-04-19 1996-04-19 Arteriovenöse und venöse transplantatbehandlungen: methoden und zusammensetzungen ATE400301T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/424,991 US6323184B1 (en) 1993-10-15 1995-04-19 Arteriovenous and venous graft treatments: methods and compositions

Publications (1)

Publication Number Publication Date
ATE400301T1 true ATE400301T1 (de) 2008-07-15

Family

ID=23684702

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96912854T ATE400301T1 (de) 1995-04-19 1996-04-19 Arteriovenöse und venöse transplantatbehandlungen: methoden und zusammensetzungen

Country Status (15)

Country Link
US (1) US6323184B1 (de)
EP (1) EP0871496B1 (de)
JP (1) JP3958362B2 (de)
KR (1) KR19990007864A (de)
CN (1) CN1177615C (de)
AT (1) ATE400301T1 (de)
AU (1) AU714658B2 (de)
BR (1) BR9608454A (de)
CA (1) CA2215631A1 (de)
CZ (1) CZ295039B6 (de)
DE (1) DE69637593D1 (de)
HU (1) HU225244B1 (de)
NO (1) NO974824L (de)
PL (1) PL188628B1 (de)
WO (1) WO1996032966A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7019498A (en) 1997-04-10 1998-10-30 Diagnocure Inc. Pca3, pca3 genes, and methods of use
US6365351B1 (en) * 1999-01-29 2002-04-02 Avi Biopharma, Inc. Non-invasive method for detecting target RNA
US6709465B2 (en) 1999-03-18 2004-03-23 Fossa Medical, Inc. Radially expanding ureteral device
US7214229B2 (en) 1999-03-18 2007-05-08 Fossa Medical, Inc. Radially expanding stents
ES2260059T3 (es) 1999-09-29 2006-11-01 Diagnocure Inc. Rna mensajero del pca3 en tejidos benignos y malignos de prostata.
JP5859179B2 (ja) * 2000-03-15 2016-02-10 オーバスネイチ メディカル、インコーポレイテッド 内皮細胞接着を促進するコーティング
AU2002249958B2 (en) * 2001-01-16 2007-11-08 Vascular Therapies, Inc. Implantable device containing resorbable matrix material and anti-proliferative drugs for preventing or treating failure of hemodialysis vascular access and other vascular grafts
US20070042983A1 (en) * 2001-05-18 2007-02-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20060241075A1 (en) * 2001-05-18 2006-10-26 Sirna Therapeutics, Inc. RNA interference mediated inhibition of desmoglein gene expression using short interfering nucleic acid (siNA)
US20050159378A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
US20050282188A1 (en) * 2001-05-18 2005-12-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20070270579A1 (en) * 2001-05-18 2007-11-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20080161256A1 (en) * 2001-05-18 2008-07-03 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
WO2003000314A2 (en) 2001-06-20 2003-01-03 The Regents Of The University Of California Hemodialysis system and method
US7893248B2 (en) * 2002-02-20 2011-02-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
EP1448590A4 (de) * 2002-02-20 2004-12-15 Sirna Therapeutics Inc Durch rna-interferenz vermittelte hemmung der myc und myb-gene oder gene der entsprechenden synthesewege
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2004209578A1 (en) 2003-02-07 2004-08-19 Diagnocure Inc. Method to detect prostate cancer in a sample
WO2004112864A2 (en) 2003-06-19 2004-12-29 Vascular Therapies Llc Medical devices and methods for regulating the tissue response to vascular closure devices
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
CA2491067A1 (en) 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
US20090176725A1 (en) * 2005-08-17 2009-07-09 Sirna Therapeutics Inc. Chemically modified short interfering nucleic acid molecules that mediate rna interference
US8827979B2 (en) 2007-03-19 2014-09-09 Insuline Medical Ltd. Drug delivery device
US9220837B2 (en) 2007-03-19 2015-12-29 Insuline Medical Ltd. Method and device for drug delivery
US8622991B2 (en) 2007-03-19 2014-01-07 Insuline Medical Ltd. Method and device for drug delivery
US8409133B2 (en) 2007-12-18 2013-04-02 Insuline Medical Ltd. Drug delivery device with sensor for closed-loop operation
US8221738B2 (en) 2008-02-19 2012-07-17 Celladon Corporation Method for enhanced uptake of viral vectors in the myocardium
EP2355758A2 (de) 2008-11-07 2011-08-17 Insuline Medical Ltd. Arzneimittelabgabevorrichtung und -verfahren
EP3766975A1 (de) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Rna-interferenz-vermittelte inhibition von genexpression unter verwendung kurzer interferierender nukleinsäure (sina)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
SE462364B (sv) 1988-09-30 1990-06-18 Goeran Hansson Anvaendning av gamma-interferon foer beredning av ett preparat foer behandling av vaskulaer stenos
US5245022A (en) 1990-08-03 1993-09-14 Sterling Drug, Inc. Exonuclease resistant terminally substituted oligonucleotides
US5122048A (en) 1990-09-24 1992-06-16 Exxon Chemical Patents Inc. Charging apparatus for meltblown webs
CA2082411A1 (en) 1991-06-28 1992-12-29 Robert D. Rosenberg Localized oligonucleotide therapy
WO1993008845A1 (en) 1991-11-08 1993-05-13 Massachusetts Institute Of Technology Localized oligonucleotide therapy
US5756476A (en) * 1992-01-14 1998-05-26 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of cell proliferation using antisense oligonucleotides
US5869462A (en) * 1992-09-10 1999-02-09 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
US5821234A (en) 1992-09-10 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
WO1994015645A1 (en) 1992-12-31 1994-07-21 Texas Biotechnology Corporation Antisense molecules directed against genes of the raf oncogene family
WO1994015943A1 (en) 1992-12-31 1994-07-21 Texas Biotechnology Corporation Antisense molecules directed against a platelet derived growth factor receptor related gene
CA2153158A1 (en) 1993-01-07 1994-07-21 Andrew Zalewski Antisense inhibition of c-myc to modulate the proliferation of smooth muscle cells
EP1027834A1 (de) 1993-06-11 2000-08-16 The Board of Trustees of The Leland Stanford Junior University L-Arginin enthaltende Nahrungsmittelzusammensetzung
EP0732940B1 (de) 1993-10-15 2001-12-19 Thomas Jefferson University Inhibierung der synthese von extrazellulärer matrix mittels "antisense"-zusammensetzungen, die gegen c-myc gerichtet sind

Also Published As

Publication number Publication date
EP0871496A1 (de) 1998-10-21
KR19990007864A (ko) 1999-01-25
CZ295039B6 (cs) 2005-05-18
CN1181706A (zh) 1998-05-13
CZ330297A3 (cs) 1998-03-18
AU5553296A (en) 1996-11-07
NO974824L (no) 1997-12-16
JP3958362B2 (ja) 2007-08-15
EP0871496A4 (de) 1998-10-21
PL323046A1 (en) 1998-03-02
AU714658B2 (en) 2000-01-06
JPH11503911A (ja) 1999-04-06
CA2215631A1 (en) 1996-10-24
US6323184B1 (en) 2001-11-27
HU225244B1 (en) 2006-08-28
HUP9800729A2 (hu) 1998-07-28
PL188628B1 (pl) 2005-03-31
WO1996032966A1 (en) 1996-10-24
CN1177615C (zh) 2004-12-01
HUP9800729A3 (en) 2000-07-28
BR9608454A (pt) 2002-02-05
EP0871496B1 (de) 2008-07-09
NO974824D0 (no) 1997-10-17
DE69637593D1 (de) 2008-08-21

Similar Documents

Publication Publication Date Title
DE69637593D1 (de) Arteriovenöse und venöse transplantatbehandlungen: methoden und zusammensetzungen
ATE233738T1 (de) Kleine moleküle anwendbar in der behandlung von entzündgskrankheiten
BR9610838A (pt) Processo para tratar um indivìduo tendo uma condição patológica envolvendo neovascularização.
DE69527847D1 (de) Verwendung von anti-vegf-mitteln zur behandlung der endometriose
NO20002788D0 (no) Nye forbindelser
BR0316487A (pt) Método todo de tratamento da rejeição de transplantes
DE69435330D1 (de) Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Behandlung von Muskelkrämpfen
DK0763055T3 (da) Perflouralkylketon-inhibitorer af elastase og fremgangsmåde til fremstilling deraf
DE69519937D1 (de) Polyamin-verbindungen zur behandlung von proliferativer erkrankungen
DE69525279D1 (de) Behandlung von Leder zum Einfärben desselben, sowie gefärbtes Leder
DE58906239D1 (de) Einrichtung zur Behandlung von Erkrankungen, insbesondere der Sehbahn.
DE69526216D1 (de) Antifungaleverfahren und mitteln
DE69328025D1 (de) Dorsalgewebe beeinflussender faktor und zusammensetzungen
ATE304371T1 (de) Verwendung von staphylococcus enterotoxin homologe für krebs-therapie
ATE196083T1 (de) Verwendung von ferrioxamin-b zur behandlung septischen schocks
DE69631381D1 (de) Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen
ES2187648T3 (es) Metodo para la administracion de farmacos para terapia genica.
ATE213163T1 (de) Verfahren zur behandlung von motorischen defiziten
MX9604762A (es) Nuevas sulfonamidas y procedimiento para su preparacion.
DE69626816D1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
ATE251462T1 (de) Verfahren zur behandlung von narbengewebe
ATE320263T1 (de) Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
ATE339423T1 (de) Verfahren zur herstellung von 4'-o-substituierten 4'-demethyl-1 desoxypodophyllotoxinderivaten und geometrischen isomeren davon ,und antikrebspräparat, das diese enthält
DE68913995D1 (de) Zusammensetzung zur behandlung progressiver myopie.
ES2138734T3 (es) Procedimiento para la preparacion de derivados de 1-(3-trialquilsililfenil)-2,2,2-trifluormetil etanona.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties